Improving treatments for patients with immune system disorders
Official title: Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunity
Funded at University of California, San Francisco · NIH-10935431 · Data updated 2026-11-12
This study is working to improve treatments and care for people with immune system disorders, like Severe Combined Immune Deficiency and Chronic Granulomatous Disease, by gathering information from doctors across the US and Canada to find out what works best for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 3, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $1,815,882 |
| NIH project number | 1R24AI184316-01 |
| Project ID | NIH-10935431 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation include children and adults diagnosed with inborn errors of immunity, particularly those with severe forms of these conditions.
✕Less likely to help
Patients with mild immune deficiencies or those not diagnosed with inborn errors of immunity may not benefit from this research.
What this research studies
The Primary Immune Deficiency Treatment Consortium (PIDTC) focuses on enhancing the treatment and outcomes for patients with inborn errors of immunity, such as Severe Combined Immune Deficiency and Chronic Granulomatous Disease. By aggregating data from 49 clinical sites across the US and Canada, the consortium aims to address critical questions regarding treatment effectiveness and patient care. This initiative involves collaboration among immunologists, bone marrow transplant physicians, and cell/gene therapists to develop a comprehensive resource that supports research and clinical advancements in this field.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and better health outcomes for patients with severe immune deficiencies.
How similar studies have gone: Previous research efforts in similar areas have shown promise in improving treatment outcomes for patients with immune deficiencies, indicating that this approach has potential for success.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Dvorak, Christopher Craig — University of California, San Francisco
- Study coordinator: Dvorak, Christopher Craig
Related research
Other NIH-funded projects on the same topics.
-
How cancer cells use exosomes to evade the immune system
This study is looking at how cancer cells use tiny bubbles called exosomes to hide proteins that can keep your immune system from fighting the tumor, and by figuring this out, the researchers hope to help doctors understand why some people respond well to cancer treatments while others don’t, ultimately aiming to creat
-
Reducing harm from smoking using electronic cigarettes
This study is looking at whether using electronic cigarettes can be a safer option for people who smoke traditional cigarettes, by comparing the health effects and exposure to harmful substances between the two.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Cutaneous opioid signals in skin inflammation
A mentor-identified clinician-researcher at UCSF is studying how natural skin opioids regulate itch and pain in inflammatory skin conditions like eczema and hidradenitis, with plans to map where these opioids come from and how they affect skin nerves.
-
Pooling international data to understand long-term bisphosphonate use and atypical femur fractures
This project combines large patient datasets from multiple countries to understand how long-term bisphosphonate use relates to rare hip and thigh bone fractures, helping doctors and patients make safer treatment choices.
-
Airway cell and immune cell talks in lung transplant failure
This grant tests how airway cells and immune cells interact to drive chronic rejection after lung transplant, with the goal of slowing or preventing scar-like damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.